Cidara Therapeutics (CDTX) to be acquired by Merck (MRK) for $9.2B or $221.50 per share

Cidara Therapeutics to be acquired by Merck (MRK) for $221.50 per share in cash

• Merck (MRK) agreed to acquire Cidara Therapeutics (CDTX) for $221.50/share in cash, valuing the transaction at ~$9.2B, as part of its strategy to broaden its infectious disease pipeline.
• Deal centers on CD388, a long-acting, strain-agnostic antiviral in Phase 3 (ANCHOR) for preventing influenza in high-risk individuals; the candidate has Breakthrough Therapy and Fast Track designations and showed strong efficacy in the Phase 2b NAVIGATE trial.
• CD388 combines a neuraminidase inhibitor with a proprietary Fc-antibody fragment, aiming to provide a durable prevention option beyond vaccines and traditional antivirals.
  
• Boards of both companies have approved the transaction; closing is expected in Q1 2026, pending a successful tender offer, HSR clearance, and customary conditions.

  

 

The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 38
• Incorporated in 2012 
• Based in San Diego, California
• https://www.cidara.com

Imago BioSciences (IMGO) to be acquired by Merck (MRK) for $36.00/share

 

 

Imago BioSciences to be acquired by Merck (MRK) for $36.00/share 

• Cos announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion.
• “This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology,” said Merck Chief Executive Robert Davis in a news release.
• 
  
• Hematology is the branch of medicine that focuses on the study of blood diseases. Imago is a clinical stage biopharmaceutical company developing new medicines for the treatment of several bone marrow diseases.